Z

Zolgensma

Product

by Novartis

Heard in 2 episodes across 1 show since Oct 2026

Zolgensma is a gene-replacement therapy for spinal muscular atrophy caused by mutations in the SMN1 gene.

Email alerts

Episodes

2
across 1 show

First heard

Oct 2026

Expert statements

1
1 positive

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20260
Oct 20261
Nov 20261

Email alert

Email me when Zolgensma comes up on a podcast

One email a week at most, with the new episodes that mention Zolgensma. Free, no account needed, unsubscribe in one click.

What experts have said about Zolgensma

1 statement · 1 positive

  1. Paul MatteisPositiveNov 6, 2026· Biotech Hangout

    Zolgensma’s risk-benefit profile remains favorable in severe SMA.

    “the risk benefit I would say is still favorable.”

    Listen at 50:24

    Open the episode · Episode 202 - November 6, 2026
Filter the statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

2 episodes featuring Zolgensma, newest first